Plain-English translation of NCT06627634 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new surgical approach for people with stomach cancer or cancer at the junction of the stomach and esophagus that has spread to the liver. If you qualify, you would receive chemotherapy (using the FLOT regimen) followed by surgery to remove your primary tumor and the cancer spots in your liver, with the goal of curing your cancer. This treatment is only available in this trial right now, and researchers want to see if it helps people live longer.
Today, when stomach cancer spreads to the liver, doctors typically cannot offer surgery with the intention to cure. This trial exists to test whether removing both the primary tumor and the liver metastases, combined with standard chemotherapy, could offer a real chance at cure for patients who currently have no such option.
You likely qualify if…
You likely don't qualify if…
You would start with chemotherapy (FLOT regimen) to shrink the tumors. Then you would undergo surgery to remove your stomach and the cancer spots from your liver. After recovery, you would be followed to monitor your health and survival. The trial will track your progress for at least 2 years to see how long you survive and whether the combined approach helps cure your cancer.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Denmark
Sponsor
Aarhus University Hospital
Collaborators
Rigshospitalet, Denmark, Aalborg University Hospital
Enrollment target
~20 participants
Started
December 2020
Primary completion
December 2024
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in October 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Julie Lykke Harbjerg, MD
Aarhus University Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.